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Background: Personalized medicine is predicated on the notion that individual biochemical and genomic profiles are
relatively constant in times of good health and to some extent predictive of disease or therapeutic response. We report
a pilot study quantifying gene expression and methylation profile consistency over time, addressing the reasons for
individual uniqueness, and its relation to N = 1 phenotypes.
Methods: Whole blood samples from four African American women, four Caucasian women, and four Caucasian men
drawn from the Atlanta Center for Health Discovery and Well Being study at three successive 6-month intervals were
profiled by RNA-Seq, miRNA-Seq, and Illumina Methylation 450 K arrays. Standard regression approaches were used
to evaluate the proportion of variance for each type of omic measure among individuals, and to quantify correlations
among measures and with clinical attributes related to wellness.
Results: Longitudinal omic profiles were in general highly consistent over time, with an average of 67 % variance in
transcript abundance, 42 % in CpG methylation level (but 88 % for the most differentiated CpG per gene), and 50 %
in miRNA abundance among individuals, which are all comparable to 74 % variance among individuals for 74 clinical
traits. One third of the variance could be attributed to differential blood cell type abundance, which was also fairly
stable over time, and a lesser amount to expression quantitative trait loci (eQTL) effects. Seven conserved axes of
covariance that capture diverse aspects of immune function explained over half of the variance. These axes also
explained a considerable proportion of individually extreme transcript abundance, namely approximately 100 genes
that were significantly up-regulated or down-regulated in each person and were in some cases enriched for relevant
gene activities that plausibly associate with clinical attributes. A similar fraction of genes had individually divergent
methylation levels, but these did not overlap with the transcripts, and fewer than 20 % of genes had significantly
correlated methylation and gene expression.
Conclusions: People express an “omic personality” consisting of peripheral blood transcriptional and epigenetic
profiles that are constant over the course of a year and reflect various types of immune activity. Baseline genomic
profiles can provide a window into the molecular basis of traits that might be useful for explaining medical conditions
or guiding personalized health decisions.* Correspondence: greg.gibson@biology.gatech.edu
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This study is an enquiry into the stability of omic “person-
alities”, namely, the degree to which functional genomic
profiles such as the transcriptome and methylome retain
individual-specific features over time. Just as humans are
able to recognize one another through facial and other
morphological (and behavioral) attributes that remain
person-specific for decades, we ask whether omic profiles
have a similar capacity to define personalities at the
molecular level. If functional genomic data types are to
be incorporated alongside genome sequences as a compo-
nent of clinical medicine [1, 2], it is essential that we have
a baseline understanding of whether diagnostic and tran-
scriptional, protein, metabolite, and epigenetic biomarkers
remain stable over time [3–5], whether perturbation in
the context of disease is transient or permanent [6], or
if behavioral interventions can push profiles to a more
healthy state.
The dataset we describe allowed us to assess the stability
of omic profiles in healthy volunteers who were part of a
wellness intervention study at Georgia Tech and Emory
Universities, the Center for Health Discovery and Well
Being (CHDWB) [7, 8]. It consists of RNA sequencing
(RNA-Seq), micro-RNA sequencing (miRNA-Seq), and
DNA methylation (Illumina Methylation 450 K array) data
from whole blood sampled three times at 6-month inter-
vals from each of 12 participants. Whole genome se-
quences and clinical values for 74 traits, also measured at
the three time points, were also available and have been
previously described for the eight European Americans
(four men and four women) in the study [9]. We added
data for four African American women. All individuals
were chosen to represent a diversity of physical and
mental health phenotypes. For the most part, the clinical
attributes did not change appreciably over the course of
the study [10] and three quarters of the variance in each
trait tended to be among individuals.
Two “straw man” alternative a priori models for the
extent of omic personality may be postulated. The first
is that gene expression and methylation are sufficiently
labile that multiple measures from any individual are un-
likely to be identifiable as belonging to one person. This
may be because blood cell type abundance fluctuates,
environmental exposures change, and people experi-
ence different health states from month to month and
week to week. For example, considerable lability of the
methylome has been observed in the first two years of
life [11, 12], as well as with advancing age [13–18]. The
opposite model would be that our omic profiles are just
as stable as our visible phenotypes, and that clustering
of any individual samples for any of the three data types
would lead to side-by-side alignment for the three samples
for each person. Our analyses unambiguously favor this
latter model, at least over a 12-month period, consistentwith the notion that people have strong omic personal-
ities. Within this model, three further sub-models may be
considered. One is that the individual-biased expression is
restricted to a limited number of genes that have relatively
strong deviations, perhaps due to cis-acting regulatory
effects that are known to explain up to 30 % (and in some
cases more) of the variance of individual transcripts
among people [19–22]. Alternatively, it could be distrib-
uted over the majority of transcripts. The third possibility
is that the individual-biased expression is highly struc-
tured such that covariance of hundreds or thousands of
transcripts along a limited number of axes of variation ex-
plains much of the individual specificity, rather than each
gene being independently regulated [23, 24]. This would
imply that trans-acting factors are more important than
cis-regulatory ones in defining a person’s omic personality.
A number of early microarray studies explored the in-
dividuality of gene expression and its relationship to
blood cell counts. In 2003, Whitney et al. [3] noted
suites of genes associated with lymphocyte, neutrophil,
and reticulocyte abundance (which essentially correspond
to Axes 1, 5, and 2 in our study defining conserved axes of
covariance in blood [21]), but only documented 340 genes
with high “intrinsic scores” in peripheral blood monocytes,
implying that they were differentially expressed among 16
individuals. By contrast, Eady et al. [5] took a more stand-
ard statistical approach and argued for individualized ex-
pression of over 3,300 genes (39 % of those represented
on their microarrays) in a study of 18 adult volunteers
sampled weekly over a month. Studies of methylation in
peripheral blood have documented much stronger cor-
relations than transcripts with age [13, 14], as well as
with gender and body mass index at many loci, but it
appears that the modular structure of methylation is
generally not correlated with that of the transcriptome
[13, 25]. Here, we quantify the correspondence between
gene expression and DNA methylation profiles in 12
adults over a year, also relating the observations to clin-
ical attributes of the study participants. The data lead
us to argue that steady-state omic profiles may well
prove to be useful in personalized medicine as markers
of individual health status.
Methods
Ethics, consent, permissions and consent to publish
We studied the profiles of 12 middle-aged individuals (39–
61 years old) chosen to represent a range of clinical profiles
in the CHDWB study [7, 8], including four African
American women (Aa, Ab, Ac, Ad), four Caucasian
women (Ce, Cf, Cg, Ch), and four Caucasian men (Mi,
Mj, Mk, Ml). The individuals all consented under the
institutional review boards approvals of both Emory
University and Georgia Tech to analysis of their gene
sequences, transcriptome, and epigenome, including
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heres to the tenets of the Helsinki Declaration and is
consistent with all relevant local regulations in Atlanta,
GA, USA. However, the individuals do not currently
consent to the right to receive feedback of their own
genomic data, and hence their identities are protected.
The same Caucasian individuals were reported in our
previous study of genotypic and clinical risk of disease
[9], but with different identifiers, again to protect priv-
acy. All data are available after approval by request to
the Data Access Committee of the CHDWB, while the
gene expression and methylation profiles are available
at the Gene Expression Omnibus [GEO:GSE67491].
Sample collection
Peripheral blood samples (10 ml) were collected into
EDTA tubes that were frozen for DNA preservation, and
Tempus RNA tubes (Life Technologies, Grand Island,
NY, USA) for preservation of RNA. Samples were taken
during regular 6-monthly visits to the Center, generally
between the hours of 10:00 a.m. and 12:00 noon. The 74
clinical traits considered here are listed in Additional file
1: Table S1 and were measured within 2 h of the blood
sampling or generated from self-reported survey assess-
ments taken within 1 week of each sample. A total of 668
individuals enrolled and have participated in the CHDWB,
which is an ongoing longitudinal study designed to evalu-
ate the impact of health coaches on wellbeing. Across the
cohort, significant improvement in most major indicators
of health including physical, biochemical, and mental
health parameters is observed [10], and is maintained for
at least 3 years, but the effects are modest and tend to be
restricted to those individuals with the highest baseline
risks.
RNA-Seq
Whole blood transcriptomes were characterized by
RNA-Seq using paired-end 100 base pair (bp) sequen-
cing on an Illumina HiSeq2000 (Illumina Inc, San
Diego, CA, USA) at the Vanderbilt University Medical
Center in 2012, with four samples per lane, randomized
with respect to individual and time point. Unstranded
TruSeq cDNA libraries were prepared using Illumina
TruSeq RNA Sample Preparation Kits (Set A, v2) from
total RNA isolated from Tempus tubes following the
manufacturer’s protocols. For eight of the individuals,
we replicated the sequencing of the same libraries using
the Yerkes NHP Genomics Core Laboratory (Atlanta, GA,
USA) in 2013. In all cases, each individual’s replicated pro-
file clustered side-by-side with the initial sample, so the
reads were combined to produce an average coverage of
approximately 50 million paired-end reads (range 40
million to 80 million), with average read depth of 40× at
the exons. As an additional quality check, we alsocontrasted the RNA-Seq profiles with microarray re-
sults available for the baseline samples, observing
complete concordance in the identity of samples with
the highest correlations across platforms.
All short reads were aligned to HuRef19 using the
TopHat spliced-reads fast mapper in Cufflinks v2.0.1
[26]. Downstream analyses were performed at the level
of the whole gene, using the Supervised Normalization
of Microarray (SNM) algorithm [27] to normalize the
log2 transformed read counts (fragments per kilobase
of transcript per million mapped reads, FPKM) with a
model fitting individual as the biological variable, and
removing effects of RNA quality and ethnicity. A total
of 11,265 expressed genes were analyzed, using FPKM >
1 as the threshold for detection in all samples.
miRNA-Seq
miRNA-Seq was similarly performed using small RNA
prepared from the identical whole RNA samples, with
Illumina TruSeq Small RNA Sample Preparation Kits,
running 18 samples per lane for an average of 7 million
reads. Six samples failed, one each for individuals Aa,
Ad, Ch, and Mk, and two for Ac. Analysis of sequence
reads was performed using miRExpress [28, 29]. The
log2 transformed reads per million counts were normal-
ized by the SNM algorithm using the same model as for
RNA-Seq data and were used for downstream analyses.
Methylation
Whole blood DNA obtained at the same time as the
RNA samples was subject to methylation profiling using
Illumina Human Methylation 450 K BeadChip arrays
following bisulfite conversion. The samples were proc-
essed by the Illumina Genome Network laboratory at
the University of Washington in parallel to the gener-
ation of whole genome sequence data, with all samples
processed concurrently to avoid batch effects [30]. These
arrays provided comprehensive coverage of over 450,000
CpG sites distributed intergenically, in CpG islands and
shores, and in gene bodies, and within 1.5 kilobases (kb)
or 200 bp of the annotated transcription start site (TSS)
of most human genes. Other annotations include
whether the CpG sites occur within DNase hypersensi-
tive sites, or are known to be differentially methylated in
tumor versus normal or across a variety of tissue types.
Methylation levels were expressed as beta values ranging
from 0 (non-methylated) to 1 (fully methylated) obtained
directly from the GenomeStudio output (Illumina, Inc.)
from scanning the bead arrays. Further transformations
including mean centering and quantile normalization
were explored, but all data reported in this manuscript
refer to the raw beta values deposited at GEO. Regret-
tably, each of the three samples for each individual were
processed on the same chip, so there is confounding of
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design file Additional file 1: Table S2. However, chip
explained less than 10 % of the variance, one fifth of that
explained by individual, and permutations imply that this
is expected by chance. Because principal component 1
(PC1), which differentiated individuals, was not associated
with slide, we elected not to adjust the chip effect to avoid
overfitting. Only autosomal probes were considered for
most analyses. Islands refer to CpG sites situated within
200 bp or greater stretches of DNA with more than 50 %
CG content and an excess of CpG; shores refer to CpG
sites within 2 kb on either side of islands, and shelves refer
to an additional 2 kb further from an island than shores.
Allele-specific expression
Allele-specific expression was estimated by generating
the counts for each short read aligned to either the
HuRef19 human reference genome or to a proxy gen-
ome sequence (referred as alternate genome) generated
for each individual containing the alternate allele at each
heterozygous site from their own whole genome se-
quence [9]. Allele-specific expression was estimated only
for sites that were confirmed heterozygous in the indi-
vidual’s whole genome sequence, and for which at least
eight reads were available containing the polymorphic
site in all three biological replicates. We chose eight
reads to compromise between including sufficient sites
for the comparison (greater depth would exclude sites
and individuals) while minimizing the impact of under-
estimation and overestimation of biases (three, four or
five out of eight produce ratios of 0.375, 0.5, and 0.625
but are within sampling variance, whereas three mea-
sures of four out of eight would underestimate variance).
Notably no correlation between read depth and bias was
observed at this level of inclusion. Three individuals (Ac,
Ad, and Ml) had fewer than 13,000 comparable sites
after applying these filters and were excluded from the
analysis, which was thus restricted to nine individuals.
Preliminary analysis shown in Additional file 2: Figure
S1A for individual Aa indicated strong tendency for
under-representation of the alternate allele in alignment
to the reference genome, whereas under the null the
average representation of each allele is expected to be
50 % (assuming that transcript abundance is independ-
ent of allele frequency and hence representation in the
reference genome); the average in most individuals was
47.4 %. This reflects in part the inclusion of probes that
are known to map differentially as reported by others
[22]. Rather than excluding such probes, we noted that
there was a continuum of differential alignment biases,
so we took an empirical approach. Comparison of the
alignments to the alternate and reference genomes indi-
cated that two thirds of the heterozygous sites had an
average 5 % or more difference in alternate allelefrequency between alignments, and only 10 % of sites
had an estimated alternate allele frequency that differed
by less than 2.5 %. Utilizing the alternate genome align-
ments results in a slight excess of expression biased to-
ward the alternate allele (average 51.6 %), but with an
approximately symmetrical distribution of biases. Add-
itional file 2: Figure S1B contrasts the estimated biases for
the reference and alternate genomes for Aa, highlighting
the strong underestimation of bias for around 5 % of
probes.
Although we report results across the full spectrum of
alleles, the proportion of sites that were significantly
biased in both the alternate and reference alignments
was almost the same regardless of the absolute concord-
ance between the two alignments. Single nucleotide
polymorphisms (SNP) rs9906320 in Aa illustrates the
problem: the proportions of the alternate allele in the
three replicates when aligned to the reference genome
were 0.39, 0.43, and 0.44, but when aligned to the alter-
nate genome were 0.51, 0.51, and 0.51, so an allele-
specific expression (ASE) bias would be inferred in the
reference alignment but not in the personalized align-
ment. Transcriptome-wide, this typically translated to a
4-fold excess of incidence of reference allele bias in
alignments to the reference genome, and a 2.5-fold excess
of alternate allele biases in alignments to the alternate
genome, though both yielded estimates of 10 % of sites
showing ASE at the 5 % significance level. Restricting the
analysis to sites that had similar estimates in the two align-
ments did not meaningfully change the proportions, so
had no qualitative impact on the conclusions regarding
the individual-specific level of ASE and their repeatability
across individuals.
Statistical analyses
Statistical analyses were performed in SAS/JMP Version
5 (SAS Institute, Cary, NC, USA) or R, and simple
correlations were assessed in Microsoft Excel. Principal
component analyses reported in Fig. 1 and Additional
file 1: Table S3 were performed by computing the first
ten PCs for each of the four omic data types (clinical,
mRNA, methylation, and miRNA) across all 36 samples
(30 for miRNA). The scree plots of the amount of vari-
ance explained by each PC differed for each data type,
suggesting that different numbers of PC were significant.
Because alternative statistical methods yield slightly differ-
ent cutoffs, and clustering algorithms also vary in their
grouping of samples, we chose to report the first ten PCs
as these generally capture 80 % of the variance, and to use
Ward’s method for the hierarchical clustering However,
note that for the clinical data, perfect clustering of all 12
individuals was seen with eight PCs [73.2 % variance
explained (VE)], while the addition of PC10 added noise,
causing the slight reordering seen in the Phenome panel
Fig. 1 Partitioning of omic profiles among individuals. a Each histogram shows the density of the percent variation for each measure (feature)
in the indicated omic class that is among individuals, based on three biological samples taken at 6 month intervals for 12 people. Pearson
correlation R-squared values were obtained from standardized trait measures (phenome, transcriptome or miRNAome), or the beta values
(methylome, since these are not normally distributed). b Two way hierarchical clustering of the first 10 principal components of the 36
samples, showing strong conservation of the summary measures within individuals across replicates, with the exception of the miRNAome.
The ten columns in each panel correspond to the first 10 PC, blue negative, red positive values
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tering was attained with ten PCs as shown, but eight individ-
uals grouped uniquely with as few as five PCs, as well as
with eight PCs (75.6 % VE). For the methylation data, stable
clustering of ten individuals was seen with eight PCs (67.7 %
VE), and this did not improve or change as more PCs were
added. However, for the miRNA data, no more than two in-
dividuals clustered together no matter how many PCs were
included. With five PCs, the numbers of individuals cluster-
ing uniquely was eight for clinical data, eight for mRNA
data, eight for methylation data, and one for miRNA data,
with 57.8, 63.1, 50.2, and 59.0 % VE, respectively.
R-squared values for all estimates of the amount of
variance among individuals were estimated as the square
of the Pearson correlation coefficient reported by SAS/
JMP. Technically, because each individual was measuredat three different times, the within-individual measures
were not true biological replicates, so are referred to as
pseudo-biological replicates. Because there were no de-
grees of freedom to assess the time-within-individual
component of variance, we chose not to report the intra-
individual variance because high values may simply have
been due to single sample measurement or technical
error. However, readers should note that the technical
noise contribution to the variance within and among indi-
viduals has not been estimated, and the among-individual
effects from the R-squared values are likely an overesti-
mate of the true differences between individuals.
Differential expression or methylation was computed
by analysis of variance (ANOVA), namely from the F-
ratio of the variation within individuals over the three
visits, to the total variance in the 36 samples. We
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value at 10−4 for identifying extreme features in each indi-
vidual, resulting in a small false discovery rate (<5 % for all
except individual Cg. A common false discovery rate
(FDR) criterion for all individuals would have resulted in
the inclusion of more genes in both analyses, so our ana-
lysis can be seen as conservative, but was favored as more
consistent given that all analyses used 11 of the same 12
individuals for the comparisons.
Results
Longitudinal conservation of omic profiles
Individuals differ with respect to their phenome, tran-
scriptome, epigenome, and miRNAome, both at the
level of single measures and whole profiles. In order to
quantify these differences, we first calculated the per-
centage of the variance in traits, transcripts, CpG
methylation levels, and miRNA abundance among indi-
viduals, and then performed hierarchical clustering on
the PCs of variation to visualize profile conservation. Both
sets of observations, summarized in Fig. 1, imply that
omic individualization in human blood is approximately
as high as phenotypic differentiation among people,
namely, that differences at the molecular level are gener-
ally highly stable over a 12-month period. Panel b of Fig. 1
reports results of hierarchical clustering of individuals
with the first ten PCs, which maximized the concordance
of individuals for the transcriptome; but, as explained in
“Methods,” the use of eight PCs maximized the concord-
ance of individuals for clinical traits.
The amount of variance for 74 standardized clinical
measures among individuals ranged from 25 % (Beck
Depression Index) to close to 99 % (body mass index),
with a mean of 74 % and standard deviation of 19 %.
Half of the traits had over 80 % of the variance among
individuals, and, correspondingly, each individual’s over-
all trait profile remained quite constant over the three
visits spaced at 6-month intervals. For seven of the 12
individuals, hierarchical clustering of the first ten PCs
resulted in the three profiles clustering together (Fig. 1b,
Phenome). For the remaining five individuals, either just
the baseline or third visit was slightly divergent. If the
clustering was performed on the actual trait values (not
shown), the similarity was even stronger, and all 12 indi-
viduals clustered uniquely, reflecting the constancy of
the metabolic traits in particular.
Similarly, for the transcriptome, the mean amount of
variance among individuals was 67 % with a standard
deviation of 15 %. One fifth of the transcripts (2,212/
11,265) had more than 80 % of the variance among indi-
viduals. This implies that inter-individual variation is not
restricted to a small number of genes but rather is ob-
served across the full spectrum of transcript abundance.
Because there was also considerable covariance oftranscript abundance, the first ten PCs captured 81.5 %
of the variance, and hierarchical clustering on these PCs
resulted in adjacency of all three time points for 11 of the
12 individuals (Fig. 1b, Transcriptome). The same result
was observed upon clustering of the individual transcripts,
providing a strong demonstration of the constancy of
transcriptomic profiles in essentially healthy individuals.
The methylome also told a similar story, although the
conservation was not quite as strong. Figure 1a shows that
considering all 356,119 autosomal CpG sites indicated by
Illumina annotation to lie in the vicinity of genes, the aver-
age amount of variance that was among individuals was
just 42 % (standard deviation 21 %), yet one third of the
sites (127,980) had more than half their variance among
individuals. A similar analysis of just the most differenti-
ated site within 9,468 expressed genes indicated a mean of
76 % variance among individuals (not shown), implying
that at least some CpG sites within almost all active genes
have divergent methylation levels that are stably main-
tained. Clustering by individual according to the first ten
PCs of all of the CpG sites, explaining 80 % of their vari-
ance, again led to adjacency of all three time points for
11 of the individuals (Fig. 1b, Methylome). Only slightly
less concordance was seen when clustering on the indi-
vidual CpG methylation levels.
Analysis of the miRNA abundance was compromised
by poor quality libraries for six of the samples. Neverthe-
less, there was a clear reduction in the level of among-
individual variance relative to the transcriptome, with a
mean of 50 % and standard deviation of 15 %. Corres-
pondingly, there was considerably less consistency of the
profiles, with the profiles for just one of the seven indi-
viduals for whom data was available at all three time
points clustering together. Five others had at least two
adjacent samples, suggesting that profiles are to some
extent individual-specific but can fluctuate over time.
The reduced individuality of the miRNA profiles may be
an artifact of the data quality, but down-sampling of the
RNA-Seq data to similar sampling levels as that observed
for the miRNA retained the individuality documented
above for the full transcriptome. In addition, the amount
of variance among individuals for transcript abundance
was constant across the full range of expression levels,
with the exception of an average 5 % increase for the most
highly expressed decile of transcripts, confirming that low
read depth alone was not responsible for reduced inter-
individual variance. We conclude that miRNA abundance
is less tightly regulated than the mRNA.
Causes of inter-individual variation in transcript abundance
There are multiple potential reasons for the high inter-
individual variability in gene expression, including cis-
eQTL effects, epigenetic modulation, and trans-regulation.
We considered each of these in turn.
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abundance of transcript and are usually defined by lin-
ear regression of expression level on genotype in a large
sample [31]. We focused here on cis-eQTL (namely,
those which act locally on a transcript within 1 Mb on
the chromosome). With just 12 individuals, most genes
have fewer than two minor allele homozygotes even at
common SNPs, so direct estimates from regression
would be unreliable. Instead, we simply asked whether
genes with already known eQTL effects in blood were
more likely to vary among individuals. We extracted
the top 1,000 genes from the blood eQTL browser [21]
and compared the percent variance explained by indi-
vidual differences with that for the 1,000 genes with the
smallest eQTL effects, truncated at p < 0.001 (at which
there is an approximate 25 % false discovery rate) and
corresponding to the 6,700th to 7,700th ranked eQTL
genes. Figure 2a shows that there was a highly significant
difference between the two groups, with a mean vari-
ance explained by individual of 74 % for the strong-Fig. 2 Genetic and epigenetic influences on inter-individual transcriptional
among individuals for the 1,000 transcripts that had the highest document
The highly significant shift in the distribution to higher R-squared values in th
the inter-individual variability. b Density contours of the regression of the
among-individual R-squared for all CpG annotated to the vicinity of the s
The methylation R-squared for the vast majority of CpG was less than the
for the same regression as in (b), but only with the peak CpG per gene, n
points have residuals of at least 0.3 beta unitseQTL group, and 65 % for the weak-eQTL group
(ANOVA, p < 10−30). The latter percentage is the same
as the mean among-individual variance for all tran-
scripts, implying no evidence for locally acting common
regulatory variants accounting for the differential expres-
sion of those genes. There was also a tendency for more
strongly expressed genes to have higher inter-individual
variability (average R-squared for the top quintile of mean
abundance was 0.72, compared with 0.65 for the other
quintiles), which may have contributed to the variance
explained by the strong eQTL. However, these results are
fully consistent with the expectation that cis-QTL do
explain in the range of 10–30 % of the variance among in-
dividuals for up to a quarter of transcripts [32].
The impact of methylation on individualized gene ex-
pression was assessed in two ways, first by contrasting the
amount of variance explained by CpG status, and more
directly by examining the correlation between methylation
and transcript abundance for each gene. First, we noted
that R-squared values for the individual effect ofdifferentiation. a The two histograms show the percent variation
ed cis-eQTL effects (Strong) and 1,000 with only weak cis-eQTL (Weak).
e strong set is consistent with cis-eQTL contributing at least a portion of
among-individual R-squared for transcript abundance on the
ame gene (within 1.5 kb of the transcription start site or in an exon).
transcript R-squared. c Density contours and individual gene points
amely the site with the largest variance among individuals. Black
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CpG (Additional file 1: Table S4), ranging from a mean of
0.43 for those in a shelf to 0.48 for those in a shore, and
0.46 for those in islands. Sites in the 3′ untranslated re-
gion (UTR) were slightly less likely to explain individual
variability (mean R-squared = 0.44) than those in gene
bodies (0.46) or within 1.5 kb of the TSS (0.47), while,
surprisingly, intergenic CpG had the highest inter-
individual variability (0.52), all with similar standard
deviations just greater than 0.2. Known differentially
methylated regions among tissues (0.55) were signifi-
cantly more likely to be differentially methylated than
all other sites, but CpG in enhancers did not show such
a tendency overall. These analyses excluded the sex
chromosomes.
Regression of the amount of variance among individuals
for methylation on that for expression of the same gene
was significant, but extremely weak overall (Fig. 2b). Of
184,294 methylation R-squared values, 13.4 % were greater
than the corresponding transcript abundance R-squared
values, which was 2 % less than that observed in permuta-
tions. Consequently, there was a slight tendency for genes
with elevated methylation among individuals to also be
differentially expressed, but the vast majority of differen-
tial expression did not correspond with altered methyla-
tion. Considering just the CpG with the greatest
individual differentiation within each gene (which we refer
to as peak CpG, Fig. 2c), two thirds of these had an inter-Fig. 3 Examples of the relationship between methylation and gene expres
a cg18938907 in GSTM1 shows a strong correlation between high expressi
correlation between low expression and hypermethylationindividual methylation R-squared value that was greater
than the corresponding transcript (6,333 of 9,468). These
were also more likely to be in promoter-proximal regula-
tory regions; whereas 18 % of all measured genic CpG
were between 1,500 and 200 bp of the TSS (while another
15 % were within 200 bp of the TSS), 28 % of the peak
CpG were annotated to this TSS1500 group, the increase
coming mostly at the expense of the gene body CpGs
whose proportion dropped from 43 % to 34 %.
In order to assess whether peak CpG explain the
transcript abundance, we computed the correlation be-
tween methylation level and transcript abundance.
Across all 184,294 autosomal genic sites, just 1.6 %
showed a significant relationship with an absolute value
of the correlation coefficient greater than 0.5. However,
17 % of the 9,468 peak CpG were in either tail, imply-
ing that methylation status for at least one site for
nearly one fifth of genes is strongly associated with
gene expression. Additional file 1: Table S5 lists the
strongest correlation for 1,710 genes for which there
was good evidence that at least one methylation site
associates with longitudinally consistent gene expres-
sion. A prominent example is shown in Fig. 3a, GSTM1,
methylation of which has been proposed as a biomarker
for predicting response to some types of cancer therapy
[33]. The CpG island site cg18938907 is located in the first
exon of GSTM1, and in each of five individuals with ele-
vated expression was unambiguously hypomethylated.sion where both measures are highly differentiated among individuals.
on and hypomethylation . b cg26338427 in DHRS4 shows partial
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quarter of cases where there was a strong correlation be-
tween inter-individual methylation and gene expression,
at least one other site in the same gene was also corre-
lated with transcript abundance. In one third of these
cases, one CpG was positively correlated and another
negatively correlated. In all cases, other CpG remained
uncorrelated. Figure 3b shows a more typical situation
for DHRS4 where both the peak methylation site and the
transcript were highly differentiated among individuals,
but the two measures were not strongly correlated. In
this example, two of the four individuals with elevated
methylation at cg26338647, a promoter-proximal CpG
island site, had very low gene expression whereas the
other two individuals had normal expression. In the
great majority of cases, though, there was no relation-
ship at all between strongly differentiated methylation
and differential gene expression [34]. We conclude that,
as with the cis-eQTL, there is a minority of up to one
fifth of genes where methylation of a subset of the CpG
explains a substantial proportion of the variable tran-
script abundance. Though the effects in these cases are
stronger than the genotype effects, differential methyla-
tion usually does not predict differential expression,
and in no case should the strong association of methy-
lation with gene expression be interpreted as simple
causation.
Three potential trans-acting sources of variation are dif-
ferential counts of major blood cell types, trans-eQTL,
and cumulative regulatory effects that generate seven
common axes of covariance of transcript abundance in
blood [24]. Because there was no power to detect trans-
eQTL in this sample, and the major loci were not ex-
pected to explain more than a few percent of the variance
[21], each only influencing a small number of transcripts,
they were not considered further.
Blood cell counts are highly differentiated among in-
dividuals, but explain only a modest proportion of the
transcriptional variance [3–5]. In this study, over 80 %
of the variance was among individuals for lymphocyte,
monocyte, neutrophil, red blood cell, and platelet counts
per milliliter of blood, but these five measures collectively
accounted for an average of just 35 % of the variance of in-
dividual transcripts (range 1–90 %, standard deviation
16 %) when fit to a multivariate regression (Additional file
1: Table S6).
Much more of the transcriptional variance was ex-
plained by seven previously identified axes of variation,
each of which was defined as the first PC of ten “blood
informative transcripts” [24] that were the most tightly
co-regulated of hundreds of correlated transcripts. More
than two thirds of the variance was among individuals for
six of the seven axes (the exception being Axis 4, 57 %)
with a maximum of 94 % for Axis 7, which was enrichedfor genes involved in interferon responses. Note that Axes
1 and 5 were highly correlated with lymphocyte and neu-
trophil counts, but the other axes did not correspond to
white blood cell counts. Collectively, the axes explained
an average of 63 % of the variance in transcript abun-
dance, similar to the amount they explain in large
cross-sectional population studies, and almost twice as
much as cell counts alone. These correlations are pre-
sented in Additional file 1: Table S7.
Individual-specific loss and gain of transcript abundance
and methylation states
The regulatory equivalent of deleterious coding variants is
extreme loss or gain of transcript abundance. Because it is
well known that each individual carries a burden of rare
coding mutations, we sought to establish whether there is a
similar gene expression burden by performing gene-specific
one-way ANOVA contrasting each individual’s three
pseudo-biological replicates against those of the other 11
individuals. With approximately 10,000 expressed genes,
just one would be expected per individual at p < 10−4, so we
took this as our significance threshold allowing for a small
false discovery rate. A total of 1,227 genes were observed to
be expressed in an individual-specific manner by these cri-
teria, 694 lost and 533 gained (these are listed in Add-
itional file 1: Table S8). Figure 4a is a heat map illustrating
this individual-biased expression. As indicated in Table 1,
one individual (Caucasian female Cg) had just a single ab-
errant transcript, while two (African American females Aa
and Ad) had more than twice the average losses.
In several instances, also documented in Table 1, spe-
cific examples of aberrant gene expression are plausibly
related to blood traits. For example, gene ontology analysis
shows that Aa had up-regulation of 17 genes (p < 10−5,
hypergeometric test) known to be responsive to the active
form of vitamin D, calcitrol—a possible response to low
blood calcium. Mi had high expression of the ferritin light
chain gene, FTL, and correspondingly high serum ferritin
and total iron capacity. Ab had impaired glucose tolerance
and low expression of several blood glucose transporters;
failed to express three genes in the homocystinuria type
Cb1C pathway, which may explain her abnormally low
glutathione and cysteine-glutathione levels; and showed
up-regulation of TUBB1, consistent with high platelet
counts because loss of function of the gene is reported to
lead to thrombocytopenia. Ad had a particularly interest-
ing profile that is discussed further in the “Discussion”
section. A few instances where the gene expression did
not correspond, superficially, to expected phenotypes were
also observed. For example, Ch had abnormally high ex-
pression of the TNF gene but it was Ac who has elevated
TNFα serum levels, while Mj had loss of expression of
multiple genes related to platelet function, but normal
platelet levels.
Fig. 4 Extreme deviations in gene expression or methylation. a Heat map of all genes significantly differentially expressed in each individual
relative to the other 11 individuals by ANOVA. Each of the three biological replicates for each individual clustered adjacent to one another, and
groups of transcripts with elevated expression (red) or reduced expression (blue) are clearly visible. In some cases, there were reciprocal patterns
for the most extreme sets, for example Aa and Ad or Mk and Ml. b Heat map of all peak CpG where one individual was at least 0.3 beta units
deviant from the sample average. Each individual had a unique set of hypomethylated sites (blue, with an excess in the African American females
Aa, Ab, Ac, and Ad), with relatively few hypermethylated sites, and a large number of sites where the distribution of beta values was bimodal
with multiple red or blue individuals
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extreme expression values, differential expression along
one or more of the Axes was likely to be a major con-
tributor to the deviation. For this analysis, we required
that the individual had the highest or lowest axis score
in the sample, and that PC1 of their differentially
expressed genes be highly correlated with that of the
ten blood informative transcripts for the corresponding
axis. Thus, Aa expression correlated with low Axis 1,
and with a very low lymphocyte to neutrophil ratio. Cf
had the opposite ratio and correspondingly high ex-
pression of Axis 5, and Mj had high expression of Axis
1 leading to gain of notable T cell signaling genes such
as CD8, CCR5, IL2RA, and IL12RB. Mi had high Axis 2,
which is enriched for erythropoiesis, and had high red
blood cell counts, while Ml expressed four genes in di-
rections expected of altered expression in leukemia
(ENC1 up-regulated; FANCA, SIDT2, and SLC22A18
down-regulated). Other examples are listed in Table 1,
and it is notable that even though the axes are defined
by positive covariance of gene expression, the enrich-
ments at either end of the distribution were in most
cases reflecting high or low expression in the expected
direction: in other words, genes that were negatively
correlated with an axis could also be differentially
expressed. This is also readily apparent in Fig. 4a, be-
cause some individuals exhibited reciprocal patterns of
gain or loss of expression. However, importantly, asso-
ciation with an axis was not sufficient for extremeexpression, as in very few cases was one of the blood
informative transcripts that define each axis individu-
ally aberrant, and clearly hundreds of other genes in
the relevant axes were also not significantly divergent
by ANOVA. Thus the coordinated regulation of gene
expression contributes to abnormality but other factors
are required to push the expression to an extreme.
Methylation does not appear to be one of those factors.
Because all peak CpG were significantly different among
individuals at p < 10−4, we focused the analysis on sites
that were more than 0.3 beta units in each individual from
the average beta of the remaining individuals, yielding
2,113 CpG sites listed in Additional file 1: Table S9. Of
these, 705 were divergent in two or more individuals,
reflecting bimodality of methylation that was not observed
transcriptionally; in a few cases, all 12 individuals were
deviant from the whole sample mean. Of the remaining
CpG that were deviant in just a single person, 1,181 were
hypomethylated and 227 hypermethylated (Fig. 4b). This
bias was particularly strong in the African American
women as is apparent in Fig. 4b. However, there was no
significant overlap in the identities of the extreme genes
that were both divergently methylated and transcribed
(7 % observed versus 11 % expected proportion of peak
CpG genes that were individual-biased).
We also asked whether there may be overlap in the
pathways represented by genes at the extremes of the
transcript and methylation profiles for each individual.
Additional file 1: Table S10 lists each of the pathways
Table 1 Clinical associations with extreme expression
Person Loss Gain Total Notable loss Notable gain With Axis Plausible association
Aa 289 55 344 GATA2, ELK1, GSTM4, GPX4 KCNJ2, PTGR2, F8,
LMNB1
Low Axis 1 Calcitrol responsive genes with low blood calcium
Low Axis 1 with low lymphocyte count
Ab 40 38 78 SLC2A9, ITGB2 TUBB1, CD59 High Axis 7 Diabetic: low sugar transporters with high blood
glucose
Predicted homocystinurea risk with low glutathione
and cysteine-glutathione
High tubulin 1 with high platelet count
Ac 38 17 55 ALS2, SMPD1
Ad 128 61 189 FUCA1, FUT4, FUT7, CA2 CR2, CD19, CD72,
RETN
High Axis 3 Low CA2 with sleep disorder
High Axis 3 with B cell activation
Protection against type 2 diabetes from resistin,
fucosidases
Ce 46 36 82 SPG7, ERCC3, COL5A3,
GSTM2
High Axis 6
Cf 19 41 60 TPM1, KCNH2, SIAE,
IRAK3
High Axis 5 Negative regulation of immunity with high IL6, IL8
High TPM1, KCNH2 with hypertension
Cg 0 1 1
Ch 28 65 93 GSTP1, MTHFR, TNF,
CEBPA
Mi 38 80 118 ADSL, GNE, ARMD3, DISC1 CLN6, FTL Low Axis 6 FTL with high ferritin, total iron capacity
High Axis 2 High Axis 2 with high red blood cell count
Mj 17 31 48 F5, FCGR2C, FCGR3A,
FCGR3B, LILRA4
CD8A, CCR5, IL2RB,
IL12RB2
High Axis 1 Unusual profile predicts aberrant immune signaling
Mk 3 9 12 SNTA1, FADS2,
COCH
Ml 14 12 26 FANCA, SIDT2, SLC22A18 ENC1 Low Axis 3 Four genes are biomarkers of leukemia in the observed
direction
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PathDB server [35, 36] to query KEGG, Reactome,
Wikipathway, and other gene sets. Considerably more path-
way enrichment was observed for the transcript than
methylation data. In a few cases the joint analysis provided
evidence for additional enrichments, notably for individual
Ac, in estrogen receptor mediated signaling, glucose trans-
portation, and kidney function. Parallel queries of the String
database of protein–protein interactions generated large
interaction networks for most individuals, but these were
no more connected than networks generated from the
same number of random gene sets of an equivalent size.
There is some evidence that miRNA may be mediating
some of the expression differences. Although miRNA
are thought to down-regulate expression of genes by
binding to the 3′ UTRs of target transcripts and desta-
bilizing the message, cancer studies have demonstrated
that the relationship between miRNA and mRNA abun-
dance is complex and that there are as many positive as
negative correlations [37–40]. That was also the case here:42 miRNA correlated with aberrant gene expression pro-
files in multiple individuals, and another 37 in a single in-
dividual (Fig. 5). The figure indicates significantly positive
and negative correlations based on the extreme gene ex-
pression measures ordered by individual along the x-axis.
Wherever a methylation or miRNA was associated with
one transcript, it tended to be associated with all of the ex-
treme transcripts in that individual because they shared
the same deviation. With the exception of Ad and Mj,
there were three or fewer methylation-transcript abun-
dance associations, and in all instances they were unique
to one person. By contrast, six miRNAs were correlated
with extreme transcripts in multiple individuals, even
though they were only associated with a subset of the tar-
get genes in each individual. These miRNA–mRNA corre-
lations are listed in Additional file 1: Table S11.
Allele-specific individualized gene expression
In addition to overall transcript abundance, it is relevant
to ask to what extent the ratio of transcription from the
Fig. 5 Correlation between differential gene expression, methylation, and miRNA abundance. Red points represent positive correlations, blue
negative, at p < 10−5. The lowest panel shows the differentially expressed genes for each individual (ordered from left to right as Aa through Ml),
nine of whom had a small number of genes negatively correlated with the major set of co-regulated transcripts that were extreme in that individual.
The middle panel shows which of 150 miRNA correlated with the transcripts, including several species of miRNA that were either positively or
negatively correlated with the extreme transcript sets in two or more individuals. The top panel shows methylation sites within 2 kb of the TSS
that correlated with transcripts; these were almost all unique to one individual
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must be due in part to cis-acting influences on transcrip-
tion, whether genetic or epigenetic, and has been shown
to correspond broadly to eQTL effects. However, de-
tailed cross-tissue comparisons imply that the regulation
is also context-specific and often influenced by factors
whose existence is inferred but not directly observed
[32]. RNA-Seq data provide an opportunity to address
the maintenance of ASE.
Sufficient read depth was available to survey ASE in
nine of the participants (see “Methods” for description of
cutoffs and procedures to account for alignment biases
[41]; we report here alignments to each individual’s own
genome as these are closer to the expected transcriptome-
wide absence of bias). Whole genome sequences were
previously generated [9], allowing independent identifica-
tion of heterozygous sites in exons, an average of 6,971 of
which were detected with at least eight reads in each of
the three biological replicate RNA-Seq samples per indi-
vidual. The standard deviation of the proportion of readsof the reference genotype was approximately 8 %, which
implies that a single measure from one sample is an unre-
liable estimate of deviation from the expected 50:50 ratio
of reference and alternate genotypes. However, the three
samples did provide some power to evaluate deviations as-
suming binomial sampling and, using a two-tailed 5 % cut-
off (|t| > 4.3, 2 degrees of freedom), 10.8 % of the
heterozygous sites showed an allelic bias (range 9.4–
12.7 %, with a trend for more sites with higher sampling
depth, and approximately the same proportion observed
with the reference genome alignment). One half of these
significant biases had a deviation in favor of either allele of
more than 10 %, and 20 % had a deviation of 20 % or
more. The proportion of sites where ASE was observed
both when the alignment was to the reference and to the
alternate genome was just under 5 %, so formally not
greater than expected by chance, but given the technical
and sampling errors as well as restriction of the analysis to
heterozygous sites, this was almost certainly an underesti-
mate. Notably as well, up to 25 transcripts per individual
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none) of the reads from one of the alleles. Occasionally,
one of the three samples was highly deviant, but it was
not possible using these data to assess whether these cases
represent biological effects or technical artifacts.
Pooling the heterozygous transcribed sites measured
in at least three of the nine individuals resulted in 7,993
comparisons of the consistency of ASE bias. ANOVA
was used to evaluate differences in the proportion of
reference alleles among individuals, resulting in an esti-
mated true negative rate, π0, of 81 %, and 325 significant
differences at p < 0.01, a four-fold enrichment. The vast
majority of these cases showed a range of biases among
individuals, including one or more unbiased individuals
(Additional file 1: Table S12). In addition, 16 cases where
one individual was a clear outlier relative to the others
were observed, as well as 40 cases where deviations from
50:50 were always observed to a similar magnitude but
in both directions (consistent with loss of linkage dise-
quillibrium between an eSNP and the transcribed SNP).
For example, position 4534608 on Chromosome 17 had
just 7 or 8 % alternate allele transcripts in Ab, Ff, and
Fh, but 85 % in Mj (it was homozygous in the remaining
individuals). These results, summarized in Additional file
1: Table S12A, suggest that while regulatory genotypes
are a common source of ASE, their effects are not ne-
cessarily consistent among individuals, and hence other
factors also modulate individual-specific ASE [42]. On
the other hand, in the pairwise comparisons of the
several thousand sites shared by any two individuals, the
correlation of the magnitude of ASE effect was always
highly significant and in the range of 0.4–0.5, further indi-
cating that ASE effects are considerably more prevalent
than those detected by our binomial sampling approach.
Discussion
The data presented in this study support the notion that
at the functional genomic level people have strongly per-
sistent peripheral blood profiles. The temporal conserva-
tion is on a par with that observed for anthropometric
and biochemical traits, so we refer to the profiles as a
person’s “omic personality”, implying that we are each as
molecularly individualized as we are morphologically and
behaviorally. Despite considerable fluctuation in blood
cell counts, technical measurement error, and well-
documented influences of the environment [43], more
than three quarters of the variation in the abundance of
individual transcript was among people. Consequently,
while not unique, our overall transcriptome profiles are
recognizable from month to month, over the course of
at least a year in healthy people.
This notion extends to the epigenome. Overall methy-
lation profiles were almost as stable as transcriptional
ones over the course of a year, though it is welldocumented that they change more over decades [11–
18]. The proportion of variance in individual CpG
methylation that was among individuals was lower than
for transcripts, but most genes had at least one site that
was more or less methylated in a subset of individuals,
and collectively these generated an epigenomic personal-
ity. Intriguingly, there was little correspondence between
the transcriptome and methylome in the sense that dif-
ferent pairs of individuals were more similar to one an-
other for the two data types, and in the majority of cases
where both transcript abundance and methylation of a
single gene were strongly individualized, the two measures
were not correlated. There were, however, several hundred
loci where the correspondence was strong. Recent cross-
sectional profiling across different classes of chromatin
motifs support the inference that differential methylation
often follows, and presumably stabilizes, activation of gene
expression, though the relationship seems to be complex
and context-dependent across tissues [35, 44–47]. Our
results are consistent with this model, but emphasize that
the relationship is restricted to a minority of genes, and
that other mechanisms must be responsible for the long-
term stability of most gene expression levels.
One such mechanism may be miRNA profiles. These
were surprisingly less stable in this study than the other
two omic measures, and it would not be possible to
identify a person from their miRNA personality. This
suggests miRNAs must work collectively to modulate
gene expression; otherwise, the broader fluctuations in
abundance would feed forward to the mRNA levels. A
recent study [48] of mouse embryonic stem cells found
that genes regulated by multiple miRNA tend to have
lower noise at the protein expression level, but suggest
that the effect is also a function of overall expression
level, being stronger for lowly expressed genes. Several
miRNAs did appear to correlate with the more extreme
abundance levels of multiple individuals, consistent with
a regulatory role, but one that involves a complex mix of
positive and negative regulation as observed in many
cancer genome anatomy studies. Mathematical modeling
will be required to evaluate whether and how strongly
miRNA can contribute to the temporal stability of
mRNA and protein levels. There are surprisingly few
studies of the global relationship between miRNA and
RNA abundance in human population samples [26, 27],
so we were unable to contrast our observations with an
external dataset.
What are the consequences of omic personality for an
individual’s health? Two aspects of personal transcrip-
tomes are particularly noteworthy: the coordinate regula-
tion along conserved axes of covariance, and the nature of
expression at the extremes.
We have recently noticed that in cross-sectional periph-
eral blood gene expression profiling datasets, between one
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is explained by correlation with seven major axes, each
defined by the covariance of ten blood informative tran-
scripts [24]. The relationship held in this relatively small
study of 12 people, such that each person had an individu-
alized axis profile as shown in Fig. 6 based on data in
Additional file 1: Table S13. The radar plots provide a
summary peripheral blood profile for each person, which
we believe can be used to as a baseline to evaluate a
person’s overall immune status. Four of the axes are
enriched for functions related to T-lymphocyte activity,
B-lymphocyte activity, inflammation, and the interferon
response (Axes 1, 3, 5, and 7 respectively), another
(Axis 2) is consistently associated with obesity [49], as
well as anxiety [50], while the roles of Axes 4 and 6 are
yet to be clarified. As first observed by Chaussabel and
colleagues [23, 51], covariance contained within these
axes is perturbed in a variety of immune diseases, and
similarly Cole and colleagues have defined a conserved
transcriptional response to adversity that is also related
to the axes and associates with multiple aspects of
mental health [52, 53]. It has also been shown that
baseline gene expression variation may predict vaccine
response [54, 55], and we have identified a subset of
Axis 1 that seems to be predictive of cardiovascular
death in a cohort with extant coronary disease [56]. InFig. 6 Variation in Axes of variation among individuals. Top PC1 scores for the
for the three biological replicates of each individual, showing that 87 % and 9
plots showing standardized Axis score for the seven major Axes indicated
periphery. c Average score for each woman in the study. d Three consec
e Three consecutive score profiles for individual Ac, showing deviation fo
health at that timeunpublished work on the full CHDWB cohort, we
observe many correlations of Axis scores with clinical
measures. It is consequently hard to argue that the
individualized profiles, reflecting regulation along gene
expression axes, does not influence each person’s im-
mune health to some degree—whether this is clinically
useful remains to be clarified.
Eleven of the 12 participants described here dis-
played several dozen to several hundred individual
gene expression measures that can be considered ex-
treme, because they were more than two standard de-
viation units divergent from the expression levels
observed in the other participants. Up to half of these
instances of deviant expression can be explained in
part by the covariance along one or more of the axes,
some can be attributed to cis-eQTL and epigenetic fac-
tors, and it is likely that cumulative trans-eQTL effects
are also contributing. In several cases, multiple genes with
related immune or blood functions were indicated, and
correspondingly the individual was the most extreme for
the relevant trait, as documented in Table 1. A caveat to
this analysis is that evaluation of any one individual was
necessarily performed by comparison with a panel of
others who may have been profiled at a different time,
and that other experimental design issues could lead to
technical confounding which may exacerbateten blood informative transcripts corresponding to a Axis 3 or b Axis 7
4 % of the variance in the scores was among individuals. Bottom Radar
with negative values near the center, high positive value the
utive score profiles for individual Ce, showing consistency over time.
r two axes at the final sample (pink), suggesting a deviation in her
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that individualized longitudinal gene expression profil-
ing has considerable potential to contribute to person-
alized medicine assessments.
Assessments at N = 1 cannot, by definition, be sup-
ported by statistical evaluation. The observation of one or
a handful of observations that make sense, picked from
thousands of possible such evaluations, does not consti-
tute a robust argument that the elevation or loss of a
particular gene explains a phenomenon such as low blood
pressure or elevation of a serum analyte. However, it is
also the case that genetic risk scores based on rigorously
established genome-wide association study evidence rarely
have convincing positive predictive value, even where their
sensitivity is high [57–59]. This is partly because those
associations are based on population averages, and ultim-
ately the effects of polymorphisms and mutations need to
be assessed within the context of an individual. Our con-
tention is that gene expression and, where possible, prote-
omic, metabolomic, immune, and other types of profile
will add substantially to our understanding of why each
person has disease susceptibilities, or,as importantly, is
protected from disease [60, 61].
As an illustration of the latter, consider the profile of
participant Ad. This individual was in her mid-60s and
had a very high percentage of body fat with a body mass
index in the overweight to obese range, yet her blood
glucose and triglycerides were perfectly normal. A possible
contributing factor was that she had aberrantly low ex-
pression of two genes involved in the breakdown of fucose
to glucose. By contrast, her aberrantly high expression of
the transcript encoding the myeloid-secreted adipocyto-
kine resistin [62] was not prima facie consistent with her
mid-range low-density lipoprotein cholesterol or the ab-
sence of any signs of diabetes [63]. This peptide is also pro
inflammatory, but participant Ad actually had the lowest
Axis 5 score in the study, consistent with generally low in-
flammatory activity including normal IL-6 and TNFα
levels. Nevertheless, the transcriptome profiling might be
clinically relevant if consideration were given to placing
her on statins to treat her high blood pressure, given
evidence that serum resistin opposes statin-mediated
reduction of cholesterol production in the liver in over-
weight people [64]. A major challenge for integrative
genomic profiling will be to be able to move beyond
association of lists of genotypes or transcripts that asso-
ciate with traits, to predictive models that explain how
personal profiles relate to individuals’ unusual conditions.
While not definitive, such models may be regarded as
hypothetical causal relationships for further investigation,
much as predicted deleterious rare alleles need additional
validation before they can be assumed to be pathogenic.
An important aspect of this endeavor will be recogniz-
ing that functional genomic measures are characterizedby strong patterns of co-regulation. This is in contrast to
genotype-oriented studies that assume explicitly that
genes are regulated independently of one another. This
follows from the fact that disease-associated SNPs in dif-
ferent genes are overwhelmingly in linkage equilibrium
with one another (disregarding population structure).
That is patently not the case for transcripts. For reasons
we dimly understand, the transcriptome, and presum-
ably proteome, is designed to produce stable patterns
of gene activity uniting hundreds and, in some cases,
thousands of gene products. These patterns are some-
times correlated with phenotypes, including disease sus-
ceptibility, in cross-sectional studies, but their utility for
personalized medicine will be a function of their stability
over time. Methylation profiles seem to change more as
people age than do transcriptome profiles, partially in re-
sponse to changes in cell type abundance, so this must be
accounted for, and they may be more difficult to interpret
in the context of assessing changes in health status. On
the other hand, once we accumulate more knowledge of
how tightly modules and axes of genes are co-regulated,
deviations of individual transcripts and methylation states
may be assessed relative to those genes that remain stable.
More extensive longitudinal profiling will indicate which
genes have high coefficients of variation, and which are
the most stable and hence most informative with respect
to an individual’s health and disease.Conclusions
Although this study only considers healthy people over
the course of a single year, it is clear that people express
an “omic personality” consisting of peripheral blood tran-
scriptional and epigenetic profiles that are relatively con-
stant and reflect various types of immune activity. Some
of these people are likely to go on to develop chronic con-
ditions in the next 10 to 20 years. Ongoing profiling may
allow us not just to ask how these profiles associate with
clinical features, but also to address the major issue of
whether baseline profiles predispose individuals to disease,
or more commonly provide a level of homeostasis that
protects them from perturbations that might otherwise
push them into a state of ill health.Additional files
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